

# Could supported weight loss reduce bowel cancer surgery complications?

<b>Submission date</b> 01/03/2023	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 13/03/2023	<b>Overall study status</b> Ongoing	<input checked="" type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 16/01/2026	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

In the UK, 42,000 people each year are diagnosed with bowel cancer. It is the fourth most common cancer. Surgery to remove the cancer is the best treatment. However, it has a risk of complications, which is doubled for people who are overweight/obese. Patients experiencing complications recover more slowly, stay in the hospital longer and need more care. This isn't good for patients or the NHS. Physical fitness and well-controlled blood sugar are linked with fewer complications from surgery. For people who are overweight, weight loss improves both of these factors so that it may reduce complications. One reliable way to lose a meaningful amount of weight in the short period before surgery (3-4 weeks) is through a low-calorie diet programme: eating only special nutritious soups and shakes (880 calories/day) that have all the necessary vitamins. With weekly support from a dietitian, most people succeed. Typically, people lose 5% of their weight within 20 days. The NHS uses a version of this programme to treat type 2 diabetes. In small-scale studies, patients with cancer who are overweight have been willing and able to take part in less intensive weight management programmes before surgery but lose little weight. However, the period before bowel cancer surgery is associated with feelings of uncertainty and anxiety, so it is unclear if patients can follow a more intensive programme.

### Who can participate?

To start to find out if this treatment is in the best interests of patients' physical and mental health, we will recruit 72 overweight patients awaiting bowel cancer surgery

### What does the study involve?

Half of the participants will be randomly allocated to continue with their usual care and half will be offered the weight loss programme. We will see whether enough patients are willing to take part, lose weight, and return for follow-up visits. We will monitor complications for 30 days after surgery and any reduction in muscle mass due to the weight loss. We will interview patients about their experiences.

This information will tell us if a full trial is worthwhile to test whether this programme can reduce complications from surgery, improve outcomes for people with bowel cancer, and if the financial costs are likely to be worth the benefits. It will also help us refine the treatment plans according to patient feedback.

The researchers discussed the study with seven patients and public representatives (PPI). They thought it was a critical study and the team included their suggestions for making it easier for patients to join the trial, stick to the programme, and attend visits. The research team will work with the PPI throughout the trial.

What are the possible benefits and risks of participating?

By taking part, participants will help the researchers find out if this treatment might help people with bowel cancer in the future. For participants in the normal care group, there are no direct benefits. Participants in the supported weight loss group may lose weight and this could reduce complications after surgery. Most people who follow the low-calorie diet do not experience side effects from it. The most common side effect is constipation and side effects are typically only mild and temporary.

Where is the study run from?

Nuffield Department of Primary Care and Health Services, University of Oxford (UK)

When is the study starting and how long is it expected to run for?

March 2022 to September 2028

Who is funding the study?

National Institute for Health and Care Research (NIHR) (UK)

Who is the main contact?

The CARE study team, [care@nds.ox.ac.uk](mailto:care@nds.ox.ac.uk) (UK)

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-supported-weight-loss-before-surgery-for-bowel-cancer-care-trial>

## Contact information

### Type(s)

Principal investigator

### Contact name

Dr Dimitrios Koutoukidis

### ORCID ID

<https://orcid.org/0000-0002-1955-7234>

### Contact details

Nuffield Department of Primary Care and Health Services  
Radcliffe Observatory Quarter  
Woodstock Road  
Oxford  
United Kingdom  
OX2 6GG  
+44(0)1865617767  
[dimitrios.koutoukidis@phc.ox.ac.uk](mailto:dimitrios.koutoukidis@phc.ox.ac.uk)

### Type(s)

Public

**Contact name**

Mr CARE trial team CARE trial team

**Contact details**

Surgical Intervention Trials Unit,  
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences  
Botnar Research Centre,  
University of Oxford,  
Nuffield Orthopaedic Centre,  
Windmill Road  
Oxford  
United Kingdom  
OX3 7HE  
+441865617767  
care@nds.ox.ac.uk

**Type(s)**

Scientific

**Contact name**

Dr Dimitrios Koutoukidis

**Contact details**

Nuffield Department of Primary Care and Health Services  
Radcliffe Observatory Quarter  
Woodstock Road  
Oxford  
United Kingdom  
OX2 6GG  
+44(0)1865617767  
dimitrios.koutoukidis@phc.ox.ac.uk

**Additional identifiers****Clinical Trials Information System (CTIS)**

Nil known

**Integrated Research Application System (IRAS)**

320173

**ClinicalTrials.gov (NCT)**

Nil known

**Central Portfolio Management System (CPMS)**

54218

**Study information**

Scientific Title

Pre-operative intentional weight loss to support post-operative recovery in patients with overweight and colorectal cancer: the CARE feasibility randomised controlled trial

**Acronym**

CARE

**Study objectives**

To assess whether progression to a definitive randomised controlled trial is justified

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Approved 23/01/2023, South Central - Oxford B Research Ethics Committee (Ground Floor, Temple Quay House, 2 The Square, Bristol, BS1 6PN, UK; +44 (0)207 104 8241; oxfordb.rec@hra.nhs.uk), ref: 22/SC/0465

**Study design**

Multi-centre feasibility parallel randomized controlled trial with embedded evaluation and optimisation of the recruitment process

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Colorectal cancer

**Interventions**

This is a randomised controlled trial to assess a low-energy total diet replacement programme with behavioural support which will also look at the feasibility of progression to a definitive trial that would assess whether the low-calorie diet before colorectal cancer surgery can help reduce complications post-surgery.

We aim to recruit 72 participants from NHS hospitals across England. Participants are expected to be involved in the study for about 2-3 months. They will be requested to attend a screening visit at the hospital and a visit 30 days after surgery. In between the visits, they will be asked to fill in questionnaires remotely (online/at home) and take part in audio-recorded telephone interviews about their experience.

Following the screening visit, participants will be randomised 1:1 to the supported weight loss group or standard care. The method of randomisation involved minimisation with a 20% random element. The two stratified variables will be performance status (0 versus 1-2) and the median age at diagnosis ( $\leq$ / $\geq$ 70 years).

**Supported weight loss (intervention)**

Participants will be asked by dietitians trained in the intervention to eat only formula products, such as soups, shakes, and bars, until 1-2 days before surgery. These products contain all the vitamins and minerals essential for good health, plenty of protein and fibre to help them feel full, but far fewer calories than most people usually eat. On average, we anticipate that they will

follow the diet for 3-4 weeks. They will get remote (phone/video) support from a dietitian weekly to support them adhere to the diet.

#### Standard care (control)

Participants in the standard-of-care group will follow their standard pre-habilitation pathway in line with their local hospital policy.

We will also conduct audio-recorded, phone/video consultations (e.g., MS Teams) and interviews with clinical and research staff about their experience of the trial.

### **Intervention Type**

Behavioural

### **Primary outcome(s)**

Feasibility to progression to a definitive randomised controlled trial is the primary objective. This will be judged based on 5 outcome measures:

1. Recruitment rate measured using the number of sites open, the total n participants recruited, and the number of participants recruited per site as documented in the study notes per month
2. Engagement rate measured using the mean proportion of phone calls answered per participant documented in the study notes at one timepoint
3. Adherence rate measured using the proportion of intervention participants with  $\geq 5\%$  weight loss documented in the study notes from baseline to the day of surgery
4. Retention rate measured using the proportion of participants documented in the study notes as attending their final follow-up (30 days post-operatively)
5. Safety profile measured using related adverse events and expected related and unexpected related serious adverse events documented in the study notes throughout the study

### **Key secondary outcome(s)**

Morbidity will be assessed from patient records at discharge and 30 days postoperatively using the Clavien-Dindo classification as follows:

1. Any morbidity
2. Morbidity by grade (II, IIIa, IIIb, IVa, IVb)

Oncological outcomes will be assessed from patient records at discharge and 30 days postoperatively using:

3. Survival (grade V)
4. Resection margins
5. Recurrence
6. New primary/secondary cancer

Operative outcomes will be assessed from patient records at discharge and 30 days postoperatively using:

7. Intraoperative blood loss
8. Operative time
9. Conversion to open surgery
10. Surgical site infection
11. Stoma rates and complications
12. Radiologically-defined anastomotic leaks
13. Time in the intensive care unit and high-dependency unit
14. Re-operation rates
15. Re-admission rates

Hospital stay will be assessed from patient records at discharge and 30 days postoperatively using:

16. Length of hospital stay (fitness to discharge)
17. Days alive and out of hospital

Anthropometry will be assessed by measuring in-person at baseline, on admission, and 30 days postoperatively using:

18. Weight
19. Fat-free mass

Fitness will be assessed by measuring in-person at baseline and 30 days postoperatively using:

20. Time for sit-to-stand test

Health-related quality of life will be self-reported at baseline, 4 days preoperatively, and 30 days postoperatively using:

21. EQ-5D-5L
22. HADS

Health-related quality of life will be self-reported at 30 days postoperatively using:

23. EORTC-QLQ-CR29

Costs and resource use will be assessed from trial records and by self-report at baseline and 30 days postoperatively using:

24. Intervention costs
25. Healthcare resource use questionnaire
26. QALYs

27. Adverse events will be self-reported throughout the study

### **Completion date**

01/09/2028

## **Eligibility**

### **Key inclusion criteria**

1. Participant is willing and able to give informed consent for participation in the study
2. Able to communicate in English or has a relative/friend/carers acting as interpreter
3. Aged 18 years or above
4. BMI  $\geq 28$  kg/m<sup>2</sup> (or BMI  $\geq 25$  kg/m<sup>2</sup> for people of Black, Asian, or minority ethnic origin)
5. Listed for curative elective colorectal resection for cancer
6. If neoadjuvant treatment is indicated, it must have been completed
7. Performance status 0-2

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

### **Age group**

Mixed

**Lower age limit**

18 years

**Upper age limit**

110 years

**Sex**

All

**Total final enrolment**

71

**Key exclusion criteria**

Current exclusion criteria as of 20/11/2023:

The participant may not enter the study if ANY of the following apply:

1.  $\geq 10\%$  self-reported weight loss in the 6 months before the screening visit
2.  $< 20$  days from the screening visit until surgery
3. Having allergy to soy
4. Documented stage 4-5 kidney disease
5. Documented severe heart failure (defined as New York Heart Association grade 3 or 4)
6. Previous bariatric surgery
7. Type 1 diabetes
8. Currently on warfarin
9. Currently on insulin with a previous episode of diabetic ketoacidosis
10. Radiological suspicion of imminent intestinal obstruction or endoscopic evidence of an impassable tumour
11. Pregnancy, breastfeeding, or planning pregnancy during the course of the trial
12. Any other significant disease or disorder which, in the opinion of the Investigator or healthcare professional, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial
13. Currently taking part in other interventional clinical trials unless agreed in advance by all trial teams (participation in observational studies is allowed)

A list of trials that co-enrolment has been agreed upon by all trial teams and a list of trials that co-enrolment has been agreed not to be allowed will be regularly updated and provided to trial sites.

---

**Previous exclusion criteria:**

The participant may not enter the study if ANY of the following apply:

1.  $\geq 10\%$  self-reported weight loss in the 6 months before the screening visit
2.  $< 20$  days from the screening visit until surgery
3. Follows an exclusively vegan diet, has lactose intolerance or has an allergy to soy
4. Documented stage 4-5 kidney disease
5. Documented severe heart failure (defined as New York Heart Association grade 3 or 4)
6. Previous bariatric surgery
7. Type 1 diabetes
8. Currently on warfarin
9. Pregnancy, breastfeeding, or planning pregnancy during the course of the trial
10. Any other significant disease or disorder which, in the opinion of the Investigator or

healthcare professional, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.  
11. Currently taking part in other interventional clinical trials unless agreed in advance by all trial teams (participation in observational studies is allowed).

A list of trials that co-enrolment has been agreed upon by all trial teams and a list of trials that co-enrolment has been agreed not to be allowed will be regularly updated and provided to trial sites.

**Date of first enrolment**

23/03/2023

**Date of final enrolment**

13/08/2024

## **Locations**

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

**Oxford University Hospitals NHS Foundation Trust**

John Radcliffe Hospital

Headley Way

Headington

Oxford

England

OX3 9DU

**Study participating centre**

**Cambridge University Hospitals NHS Foundation Trust**

Addenbrookes Hospital

Cambridge

England

CB2 0AU

**Study participating centre**

**Royal Devon University Healthcare NHS Foundation Trust**

Royal Devon University NHS Ft

Barrack Road

Exeter

England

EX2 5DW

**Study participating centre****Dorset County Hospital NHS Foundation Trust**

Dorset County Hospital

Williams Avenue

Dorchester

England

DT1 2JY

**Study participating centre****University Hospitals Dorset NHS Foundation Trust**

Poole Hospital

Longfleet Road

Poole

England

BH15 2JB

**Study participating centre****North West Anglia NHS Foundation Trust**

Peterborough City Hospital

Bretton Gate

Bretton

Peterborough

England

PE3 9GZ

**Study participating centre****University Hospitals of Derby and Burton NHS Foundation Trust**

Royal Derby Hospital

Uttoxeter Road

Derby

England

DE22 3NE

**Sponsor information****Organisation**

University of Oxford

ROR

# Funder(s)

**Funder type**

Government

**Funder Name**

National Institute for Health and Care Research

**Alternative Name(s)**

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United Kingdom

# Results and Publications

**Individual participant data (IPD) sharing plan**

The datasets generated during and/or analysed during the current study will be stored in a non-publicly available repository (to be determined following the publication of results)

**IPD sharing plan summary**

Stored in non-publicly available repository

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		01/12/2025	06/01/2026	Yes	No
<a href="#">Protocol article</a>		31/07/2023	21/08/2023	Yes	No
<a href="#">HRA research summary</a>			28/06/2023	No	No
<a href="#">Other publications</a>	Participants' perspectives	05/07/2024	08/07/2024	Yes	No
<a href="#">Statistical Analysis Plan</a>	version 1.0	14/03/2023	16/03/2023	No	No
<a href="#">Statistical Analysis Plan</a>	version 2.0	07/10/2024	08/11/2024	No	No
<a href="#">Statistical Analysis Plan</a>	version 1.0	07/10/2024	08/11/2024	No	No
<a href="#">Study website</a>		11/11/2025	11/11/2025	No	Yes